Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects at least 12 years old and in good general health.~* Mild to moderate plaque-type psoriasis~Exclusion Criteria:~* Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs; or to any component of the investigational formulations~* History of hypercalcemia or of vitamin D toxicity.~* Diagnosis of generalized pustular or erythrodermic exfoliative psoriasis.~* Other serious skin disorder or any chronic medical condition that is not well controlled.~* Use of non-biologic systemic anti-psoriatic therapy or biologic therapy within four weeks of enrollment.~* Use of topical therapies that have a known beneficial effect on psoriasis, within 2 weeks of enrollment.~* Systemic medications for other medical conditions that are known to affect psoriasis within the past four weeks of enrollment.~* Use of any investigational therapy within 4 weeks of enrollment.~* Pregnant women, women who are breast feeding, or sexually active women of child bearing potential who are not practicing an acceptable method of birth control.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- U0267 foam (Type: EXPERIMENTAL): U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
- Vehicle foam (Type: PLACEBO_COMPARATOR): Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.

Based on this trial design, predict the completion outcome and termination type (if applicable).